BridgeBio Pharma, Inc. Share Price & Technical Analysis
BBIO · $69.12 (-1.65%)
Healthcare / Biotechnology
$69.12
-1.65%
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin…
Price chart
Seasonality
May has 1 positive and 4 negative years (last 5 years shown)
-2% return in May, -3% avg return in past 3 year May month.
-3% return in 2026, 102% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 1% | -13% | 15% | -5% | -2% | – | – | – | – | – | – | – | -3% |
| 25 | 23% | 4% | 0% | 14% | -11% | 25% | 10% | 11% | 2% | 21% | 15% | 6% | 120% |
| 24 | -14% | -1% | -9% | -17% | 8% | -12% | 2% | 8% | -10% | -8% | 15% | 2% | -36% |
| 23 | 19% | 23% | 46% | -13% | -6% | 25% | 101% | -13% | -13% | -1% | 11% | 42% | 222% |
| 22 | -42% | -22% | 29% | -21% | -14% | 32% | -4% | 24% | -5% | 2% | -12% | -19% | -52% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Emerging · Neutral
BridgeBio Pharma, Inc., a biopharmaceutical company, discovers, develops, and delivers medicines for patients with genetic diseases. The company offers Attruby, a next-generation oral small molecule near-complete TTR stabilizer for the treatment of cardiomyopathy of wild-type or transthyretin-mediated amyloidosis (ATTR-CM); Fosdenopterin, an intravenous formulation of synthetic cyclic pyranopterin monophosphate for the treatment of molybdenum cofactor deficiency under the NULIBRY brand name; and low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 clinical stage or the treatment of children with achondroplasia and hypochondroplasia. It also develops Encaleret, an oral small molecule, negative allosteric modulator of the calcium sensing receptor, which is in phase 3 clinical study for the treatment of Autosomal Dominant Hypocalcemia Type 1(ADH1) and Chronic Hypoparathyroidism (CHP); BBP-418, an investigational, orally administered, and small molecule therapy that is in phase 3 clinical study for the treatment of LGMD2I; and BBP-812, an investigational adeno-associated virus (AAV) gene therapy for Canavan disease. In addition, the company engages in developing products for mendelian, oncology, and gene therapy diseases. It has license and collaboration agreements with the Bayer Consumer Care AG, Alexion Pharma International Operations Limited Company, Leland Stanford Junior University, and Novartis International Pharmaceutical Ltd. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$12.69B
P/E ratio
—
52W high
$84.94
52W low
$31.77
Volume
18,26,430
Beta
1.02
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is BridgeBio Pharma, Inc. share price today?
- BridgeBio Pharma, Inc. (BBIO) last traded around $69.12 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does BBIO have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for BBIO. Download the app for real-time alerts.
- How can I analyze BridgeBio Pharma, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.